Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Dow
McKinsey
AstraZeneca
Colorcon

Last Updated: May 19, 2022

Baxter Hlthcare Company Profile


✉ Email this page to a colleague

« Back to Dashboard

Summary for Baxter Hlthcare
International Patents:49
US Patents:15
Tradenames:318
Ingredients:119
NDAs:205

Drugs and US Patents for Baxter Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baxter Hlthcare CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER amino acids; dextrose INJECTABLE;INJECTION 020734-018 Sep 29, 1997 RX No No See Plans and Pricing See Plans and Pricing
Baxter Hlthcare Corp BUTORPHANOL TARTRATE PRESERVATIVE FREE butorphanol tartrate INJECTABLE;INJECTION 075695-001 Oct 23, 2001 DISCN No No See Plans and Pricing See Plans and Pricing
Baxter Hlthcare PLASMA-LYTE A IN PLASTIC CONTAINER magnesium chloride; potassium chloride; sodium acetate; sodium chloride; sodium gluconate INJECTABLE;INJECTION 017378-002 Nov 22, 1982 RX Yes Yes See Plans and Pricing See Plans and Pricing
Baxter Hlthcare Corp NOURESS cysteine hydrochloride SOLUTION;INTRAVENOUS 212535-001 Dec 13, 2019 DISCN Yes No 10,583,155 See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Baxter Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Baxter Hlthcare BREVIBLOC esmolol hydrochloride INJECTABLE;INJECTION 019386-007 May 28, 2003 4,593,119*PED See Plans and Pricing
Baxter Hlthcare Corp DOXIL (LIPOSOMAL) doxorubicin hydrochloride INJECTABLE, LIPOSOMAL;INJECTION 050718-002 Jun 13, 2000 5,213,804 See Plans and Pricing
Baxter Hlthcare CYTOXAN (LYOPHILIZED) cyclophosphamide INJECTABLE;INJECTION 012142-009 Dec 10, 1985 4,537,883 See Plans and Pricing
Baxter Hlthcare LYOPHILIZED CYTOXAN cyclophosphamide INJECTABLE;INJECTION 012142-007 Dec 10, 1985 4,537,883 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for BAXTER HLTHCARE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Inhalation 99.90% ➤ Subscribe 2008-09-11
➤ Subscribe Injection 10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags ➤ Subscribe 2014-01-31

Supplementary Protection Certificates for Baxter Hlthcare Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0489070 300162 Netherlands See Plans and Pricing PRODUCT NAME: BIVALIRUDINE; FIRST REGISTRATION,DATE: EU/1/04/289/001, 20040920
2673237 LUC00111 Luxembourg See Plans and Pricing PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; AUTHORISATION NUMBER AND DATE: EU/1/17/1173 20180326
0306228 SPC/GB01/002 United Kingdom See Plans and Pricing PRODUCT NAME: 5-(4-(2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY) BENZYL)-2,4-THIAZOLIDINEDIONE, "ROSIGLITAZONE" ITS TAUTOMERS, PHARMACEUTICALLY ACCEPTABLE SALTS, SUCH AS THE MALEATE, AND PHARMACEUTICALLY ACCEPTABLE SOLVATES.; REGISTERED: CH 55176 02 19990929; CH 55176 03 19990929; CH 55176 04 19990929; UK EU/1/00/137/001 20000711; UK EU/1/00/137/002 20000711; UK EU/1/00/137/003 20000711; UK EU/1/00/137/004 20000711; UK EU/1/00/137/005 20000711; UK EU/1/00/137/006 20000711; UK EU/1/00/137/007 20000711; UK EU/1/00/137/008 20000711; UK EU/1/00/137/009 20000711; UK EU/1/00/137/010 20000711; UK EU/1/00/137/011 20000711; UK EU/1/00/137/012 20000711
1224170 SPC/GB15/018 United Kingdom See Plans and Pricing PRODUCT NAME: NINTEDANIB*, THE TAUTOMERS AND THE SALTS THEREOF, IN PARTICULAR NINTEDANIB AND PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF, SPECIFICALLY NINTEDANIB ESILATE. *NINTEDANIB IS 3-Z-(1-(4-N-((4-METHYL-PIPERAZIN-1-YL)-METHYLCARBONYL)-N-METHYL-AMINO)-A; REGISTERED: UK EU/1/14/954/001 20141125; UK EU/1/14/954/002 20141125; UK EU/1/14/954/003 20141125; UK EU/1/14/954/004 20141125
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Colorcon
AstraZeneca
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.